jamunjar-logo
whatsapp
cartmembermenu

Search for

"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Noninvasive prenatal Screening (NIPS/NIPT)

Pregnancy
image

Report in 360Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Screens for fetal chromosomal abnormalities

₹11,999₹15,000

20% OFF

FREE:

Ai Insights

|

Home pickup

Noninvasive Prenatal Screening (NIPS/NIPT) - Comprehensive Medical Test Information Guide

  • Why is it done?
    • Test Purpose: NIPS is a screening test that analyzes cell-free fetal DNA (cfDNA) from maternal blood to detect chromosomal abnormalities in the fetus, primarily trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). The test can also detect sex chromosome abnormalities (monosomy X/Turner syndrome) and microdeletions depending on the testing platform used.
    • Primary Indications: Routine screening in all pregnant individuals (recommended by ACOG, SMFM, and other professional organizations); Advanced maternal age (≥35 years); Abnormal first-trimester screening results; Family history of chromosomal abnormalities; Previous pregnancy with chromosomal abnormality; Ultrasound findings suggestive of chromosomal abnormality; Maternal concerns or anxiety about fetal abnormalities.
    • Timing: Performed between 10 and 14 weeks of gestation (earliest at 9 weeks 6 days); Can be done as a component of combined first-trimester screening or as a standalone test; Results typically available within 7-14 days; May be used as a follow-up to abnormal first-trimester screening.
  • Normal Range
    • Normal/Negative Results: Low risk for trisomy 21, trisomy 18, trisomy 13, and sex chromosome abnormalities; Fetal fraction typically represents 10-20% of total cfDNA in maternal circulation; Risk estimate <1:1000 for each condition screened; Results reported as 'Negative,' 'Low Risk,' or 'Screen Negative.'
    • Abnormal/Positive Results: High risk for trisomy 21, trisomy 18, trisomy 13, monosomy X, or other chromosomal abnormalities; Risk estimate typically >1:100 (varies by laboratory and individual factors); Results reported as 'Positive,' 'High Risk,' 'Screen Positive,' or 'Abnormal.'
    • No Result/Inconclusive Findings: Low fetal fraction (<4% typically); Insufficient DNA quality or quantity; Maternal factors affecting result interpretation; May require repeat testing in 2-3 weeks or alternative testing methods.
    • Units of Measurement: Risk ratios (e.g., 1:100, 1:1000); Percentages for risk assessment; Z-scores for some platforms; Parts per million (ppm) for fetal fraction measurements.
    • Interpretation Classification: This is a screening test (not diagnostic); Positive results require confirmation with diagnostic testing (amniocentesis or chorionic villus sampling); Cannot rule out genetic disorders not specifically screened; Approximately 99% specificity and 95-99% sensitivity for trisomy 21 depending on maternal age and other factors.
  • Interpretation
    • Negative/Low-Risk Result Interpretation: Low probability of chromosomal abnormality; Does not eliminate all risk (residual risk exists); Specific risk estimates provided based on maternal age, gestational age, and fetal fraction; Counseling should emphasize this is screening, not diagnosis; Most pregnancies with negative results result in healthy births.
    • Positive/High-Risk Result Interpretation: Increased risk of chromosomal abnormality in the fetus; Not confirmatory diagnosis; Diagnostic testing (amniocentesis or CVS) strongly recommended; Genetic counseling essential before and after positive results; PPV (Positive Predictive Value) varies by maternal age and specific condition (higher in older maternal age); Need to explain difference between screening and diagnostic testing.
    • Sex Chromosome Abnormality Results: Monosomy X (Turner syndrome): High risk indicating absence of one X chromosome; Trisomy X: High risk indicating extra X chromosome in females; XXY (Klinefelter syndrome): High risk in males with extra X chromosome; XYY: High risk in males with extra Y chromosome; Many sex chromosome abnormalities have variable clinical presentations.
    • Factors Affecting Test Interpretation: Maternal age (strong predictor of chromosomal abnormality risk); Gestational age at testing (affects fetal fraction and test performance); Fetal fraction adequacy (insufficient fetal fraction reduces test accuracy); Maternal weight (higher BMI may affect fetal fraction); Multiple gestations (affects interpretation; most tests recommend against use in triplet or higher); Maternal conditions (mosaicism, aneuploidy may complicate results); Laboratory methodology and quality assurance standards.
    • Clinical Significance of Result Patterns: Discordant results in twins (one abnormal, one normal): Challenging interpretation; indicates possible selective aneuploidy; Consistent results in twins: May reflect shared or separate chromosomal abnormalities; Microdelection results: Extended NIPS panels may detect 22q11.2 deletion, 1p36 deletion, or other microdeletions with variable clinical significance; Normal NIPS with abnormal ultrasound: Consider other etiologies or diagnostic testing (CVS/amniocentesis); Positive results with multiple chromosomal abnormalities: Suggests maternal aneuploidy or other complication.
  • Associated Organs
    • Primary Organ Systems Involved: Fetal chromosomes (overall genetic makeup); Placenta (source of cell-free fetal DNA); Multiple organ systems potentially affected by chromosomal abnormalities including central nervous system, cardiac, gastrointestinal, genitourinary, skeletal, and endocrine systems.
    • Trisomy 21 (Down Syndrome) - Associated Findings: Intellectual disability (moderate to severe); Cardiac defects (50% incidence): AV canal defects, VSD, ASD; Gastrointestinal abnormalities: duodenal atresia, tracheoesophageal fistula, anorectal malformations; Hematologic abnormalities: increased risk of leukemia; Thyroid disease; Vision and hearing impairment; Increased risk of respiratory infections; Atlantoaxial instability; Increased maternal and fetal complications.
    • Trisomy 18 (Edwards Syndrome) - Associated Findings: Severe intellectual disability and developmental delay; Severe cardiac defects (90%): polyvalvular disease, ASD, VSD; Craniofacial abnormalities: micrognathia, low-set ears; Hand abnormalities: clenched fists with overlapping fingers; Renal abnormalities; Growth restriction; High perinatal mortality (50-90% fetal loss or death in first year); Rare surviving infants typically have profound disability.
    • Trisomy 13 (Patau Syndrome) - Associated Findings: Severe intellectual disability; Holoprosencephaly and other CNS abnormalities; Facial defects: cleft lip/palate, cyclopia, proboscis; Congenital heart disease (80%); Renal and urogenital abnormalities; Polydactyly; Microphthalmia or anophthalmia; Growth restriction; Very high perinatal mortality (up to 95% fetal loss or first-year death).
    • Sex Chromosome Abnormalities - Associated Findings: Monosomy X (Turner): Short stature, gonadal dysgenesis, cardiac defects (bicuspid aortic valve), renal abnormalities, hearing loss, learning difficulties (variable severity); XXY (Klinefelter): Usually phenotypically normal with tall stature, infertility, gynecomastia in some; Trisomy X: Usually asymptomatic or minimal symptoms; XYY: Usually phenotypically normal with tall stature, normal intelligence in most cases.
    • Potential Complications and Risks: Pregnancy loss with abnormal chromosomes (spontaneous abortion more common with trisomies); Intrauterine growth restriction; Polyhydramnios or oligohydramnios; Preeclampsia with abnormal pregnancies; Preterm labor; Need for intensive perinatal care; Long-term disability requiring extensive medical and educational support; Significant family and financial implications.
  • Follow-up Tests
    • After Negative/Low-Risk NIPS Results: Routine obstetric care and monitoring; Second-trimester anatomy ultrasound (typically 18-22 weeks) to assess for structural abnormalities; Continued prenatal surveillance with no additional genetic testing needed unless new clinical indications; Delivery planning with routine obstetric care; No specific genetic follow-up required in most cases.
    • After Positive/High-Risk NIPS Results: Genetic counseling (strongly recommended before confirmatory testing); Diagnostic testing options: Amniocentesis (typically after 15-16 weeks gestation with <1% miscarriage risk) or Chorionic Villus Sampling (CVS at 10-13 weeks with slightly higher miscarriage risk ~0.2-0.5%); Detailed ultrasound evaluation by maternal-fetal medicine specialist; Level II/III prenatal ultrasound to assess for structural abnormalities; Fetal echocardiography (if cardiac defects suspected); Counseling regarding prognosis and management options.
    • After No Result/Inconclusive NIPS: Repeat NIPS in 2-3 weeks (fetal fraction often improves with advancing gestational age); Alternative testing: Detailed ultrasound with markers for aneuploidy (nuchal translucency, nasal bone); Consider diagnostic testing (amniocentesis or CVS) if repeat NIPS again inconclusive; Sequential screening with first-trimester markers; Discussion of risks and benefits of each approach.
    • After Confirmed Chromosomal Abnormality (via diagnostic testing): Comprehensive genetic counseling; Detailed fetal anatomy ultrasound and fetal echocardiography; Pediatric and specialty consultations (cardiology, neurology, etc.) as needed; Discussion of management options and birth planning; Parental counseling regarding prognosis and support resources; Neonatal planning if continuing pregnancy; Documentation of karyotype for medical records; Consideration of recurrence risk for future pregnancies.
    • Complementary and Related Tests: First-trimester combined screening (maternal serum PAPP-A, hCG; nuchal translucency ultrasound); Quad screen/quadruple screen (second-trimester maternal serum markers: AFP, hCG, uE3, inhibin A); Integrated screening (combines first and second-trimester markers); Contingent screening (initial test determines need for additional testing); Traditional karyotype from amniocentesis/CVS; Chromosomal microarray (CGH-array) from fetal samples; Whole genome sequencing (WGS) or whole exome sequencing (WES) as research or advanced diagnostic options; Cell-free fetal DNA from maternal blood (baseline NIPS test and confirmatory testing).
    • Monitoring and Follow-up Frequency: Routine prenatal visits (every 4 weeks until 28 weeks, every 2 weeks until 36 weeks, weekly until delivery for normal pregnancies); More frequent monitoring if abnormality confirmed (individualized based on specific diagnosis); Ultrasound surveillance as clinically indicated; Coordination with maternal-fetal medicine and pediatric specialists as needed; Additional imaging or testing based on specific chromosomal abnormality and associated complications.
  • Fasting Required?
    • Fasting Requirement: NO - Fasting is NOT required for NIPS testing. The test analyzes cell-free fetal DNA present in maternal blood plasma, which is not affected by fasting status or food intake.
    • Patient Preparation: No fasting required; Patient can eat and drink normally before the test; No special dietary restrictions; No fluid restrictions; Test can be performed at any time of day without regard to meal timing.
    • Pre-Test Instructions: Confirm gestational age (ideally dating ultrasound); Verify patient identification and demographic information; Document maternal age, maternal weight, and relevant medical history; Confirm test ordering and test panel (standard trisomy screening vs. extended NIPS with microdeletions); Ensure informed consent and pre-test counseling completed; Address any questions regarding test purpose, limitations, and follow-up procedures; Confirm patient understanding that NIPS is a screening test, not diagnostic.
    • Medications - No Restrictions: No medications need to be discontinued before NIPS; Patient should continue taking all prescribed prenatal vitamins and medications as directed; Prenatal vitamins (iron, folic acid, calcium) do not affect test results; Routine medications for chronic conditions should be continued; No drug interactions with NIPS testing.
    • Specimen Collection: Simple blood draw: 10-20 mL of peripheral venous blood collected in specialized cell-free DNA collection tubes (specific tube types vary by laboratory); Collection tube type is laboratory-specific and must be used to preserve cell-free fetal DNA integrity; Sample should be processed and sent to laboratory per protocol (timing varies); No special collection procedures required; Routine venipuncture technique; Specimen label must include patient identifiers, collection date/time, and gestational age.
    • Optimal Timing and Conditions: Perform test between 9 weeks 6 days and 14 weeks gestation (or up to 22-23 weeks depending on laboratory); Optimal gestational age is 10-14 weeks (fetal fraction typically adequate); Fetal fraction increases with advancing gestational age (improves test performance later in pregnancy); Room temperature and natural light acceptable for test administration; Anxiety or stress does not affect test results; Maternal position (sitting or lying down) does not affect results.

How our test process works!

customers
customers